|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
3 June 2019 |
|
Main ID: |
ChiCTR1900023476 |
|
Date of registration:
|
2019-05-30 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Multicenter, prospective and open clinical study for rapamycin in the treatment of autoimmune hemolytic anemia
|
|
Scientific title:
|
Multicenter, prospective and open clinical study for rapamycin in the treatment of autoimmune hemolytic anemia |
|
Date of first enrolment:
|
2019-07-01 |
|
Target sample size:
|
1:20;2:20;3:20;4:20; |
|
Recruitment status: |
Pending |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=38735 |
|
Study type:
|
Observational study |
|
Study design:
|
Single arm
|
|
Phase:
|
0
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Shao Zonghong
|
|
Address:
|
154 Anshan Road, Heping District, Tianjin, China
|
|
Telephone:
|
+86 13802036467 |
|
Email:
|
shaozonghong@sina.com |
|
Affiliation:
|
Tianjin Medical University General Hospital |
|
|
Name:
|
Xing Limin
|
|
Address:
|
154 Anshan Road, Heping District, Tianjin, China
|
|
Telephone:
|
+86 13752226675 |
|
Email:
|
xinglm@tmu.edu.cn |
|
Affiliation:
|
Tianjin Medical University General Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Diganosed AIHA patients according to Criteria of diagnosis and curative effect of haematopathy and Chinese expert consensus on the diagnosis and treatment of autoimmune hemolytic anemia (2017).
2. Aged=16 years, male and female;
3. Signed informed consent.
Exclusion criteria: 1. Pregnant or breast-feeding women;
2. Obvious abnormality of liver and kidney function (BUN, ScR, ALT and AST were more than 2.5 times of the normal upper limit);
3. Active viral hepatitis;
4. Severe infection;
5. With lesion of heart, brain and kidney etc..
Age minimum:
Age maximum:
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Autoimmune
|
|
Intervention(s)
|
|
1:glucocorticoid;2:glucocorticoid & Ciclosporin;3:glucocorticoid & rapamycin;4:rapamycin;
|
|
Primary Outcome(s)
|
|
Hemolysis;
|
|
Source(s) of Monetary Support
|
|
Clinical Founding
|
|
Ethics review
|
Status: Approved
Approval date:
Contact:
Jin Donglai
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|